论文部分内容阅读
随着对PG研究的深入,消炎痛等非类固醇抗炎药作为PG合成抑制剂在治疗上引起注意,下面就消炎痛通过对PG合成抑制在临床的新用途,介绍如下: 一、在心血管方面治疗早产婴动脉导管未闭症(简称PDA),并发呼吸窘迫综合征(简称RDS)。1976年Friedman报告用单剂消炎痛治疗6例PDA合并RDS的早产儿获得成功,其中5例DA完全闭合。Heymann使用小剂量(0.1～0.3毫克/公斤)消炎痛治疗15例PDA早产儿,14例取得显著效果。Friedman等再次报告50例早产儿应用消炎痛治疗后,其中49例有效。目前文献已有100多例成功的报道,用消炎痛
With the deepening of PG research, non-steroidal anti-inflammatory drugs such as indomethacin as PG synthesis inhibitors in the treatment of attention, the following indomethacin inhibition of PG synthesis in clinical new uses, described as follows: First, in cardiovascular Treatment of premature infantile ductus arteriosus (PDA), complicated by respiratory distress syndrome (RDS). In 1976, Friedman reported successful single-dose indomethacin treatment of 6 premature infants with PDDS and RDS, of which 5 were completely closed. Heymann used a small dose (0.1-0.3 mg / kg) of indomethacin in 15 PDA preterm infants and 14 achieved significant results. Friedman and other reports once again reported 50 cases of preterm children treated with indomethacin, of which 49 cases were effective. The current literature has more than 100 successful reports, with indomethacin